Wall Street analysts are maintaining Buy rating on Cerner Corporation (NASDAQ:CERN) company shares. The one year target on the name currently stands at $64.00. The stock recently touched $53.14 and has moved in the range of $52.70 - 53.41 during the current session. Based on a recent bid this places the stock +7.16% away from the 52-week floor of $49.59 and -29.82% away from the 52-week ceiling of $75.72.
When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary. Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth. Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year. Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.
DENTSPLY International Inc. (NASDAQ:XRAY) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $66.00 on the stock. The stock is currently trading +3.35% away from its 200-day moving average of $58.05. Based on a recent trade, shares of DENTSPLY International Inc. are -5.78% away from the 52-week high of $63.68 and +21.26% away from the 52-week low of $49.48.
Analysts are estimating that the company will report earnings of $2.76 for the current year and $0.74 for next quarter. The stock closed the most recent trading session at $60.72.
Shares of Lumos Networks Corp. (NASDAQ:LMOS) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $17.50 price target and Buy rating according to the covering analysts. During today’s session the stock hit $12.75 or -0.70% from the previous close, while moving in the range of $12.70 - 12.90.
Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $4.17 price target according to the covering analysts. During today’s session the stock hit $1.30 or +3.08% from the previous close, while moving in the range of $1.31 - 1.39. This puts the stock -70.09% away from the 52-week high of $4.48 and +88.73% away from the 52-week low of $0.71.
Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm. The consensus rating simply provides an average of those recommendations. It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.